Clinical study of Cuofeng San in the treatment of anterior circulation cerebral infarction in patients with syndrome of wind and phlegm blocking collaterals

doi:10.11958/20250305

Abstract

Abstract:

Objective To observe the efficacy of Cuofeng San in the treatment of anterior circulation cerebral infarction (ACCI) of patients with syndrome of wind and phlegm blocking collaterals. Methods A total of 150 ACCI patients were collected in this study，and they were divided into the control group and the treatment group using a random number table method, with 75 cases in each group. The control group was given standardized intervention according to the stroke diagnosis and treatment guidelines, while the treatment group was treated with modified Cuofeng San on the basis of the control group. Both groups were treated continuously for 2 weeks. The treatment effects were compared between the two groups before and after treatment, including the National Institutes of Health Neurological Impairment Scale (NIHSS) score, Barthel Index (BI) score of daily activity ability, scores of syndrome of wind and phlegm blocking collaterals, serum levels of neuron specific enolase (NSE), S100 calcium binding protein B (S100B), monocyte chemoattractant protein-1 (MCP-1) and vascular endothelial cell calcium binding protein (VE-cadherin). Results The total effective rate of ACCI patients was higher in the treatment group than that in the control group (93.3% vs. 81.3%, P<0.05). After 1 week and 2 weeks of treatment, the NIHSS score and wind phlegm obstruction syndrome score decreased in both groups compared to those before treatment, while the BI score increased, and the improvement was more significant in the treatment group (P<0.05). After the end of the treatment course, serum levels of NSE, S100B, MCP-1 and VE-cadherin decreased compared to those before treatment, and the decrease was more significant in the treatment group (P<0.05). Conclusion The modified Cuofeng San has a significant effect on the treatment of wind phlegm obstruction syndrome in patients with ACCI acute phase. It can improve neurological function and enhance daily activity ability.

Key words: cerebral infarction, stroke, cerebrovascular circulation, cuofeng san, neuron specific enolase, S100 calcium binding protein B, monocyte chemoattractant protein-1, vascular endothelial cell cadherin

CLC Number:

R743.33

Figures/Tables 6

References 21

[1]	WANG X, LUAN X, YANG Z. The effect of butylphthalide on improving the neurological function of patients with acute anterior circulation cerebral infarction after mechanical thrombectomy[J]. Medicine (Baltimore), 2023, 102(34):e34616. doi:10.1097/MD.0000000000034616.
[2]	ZENG H, ZHOU J, HUANG C, et al. Clinical application of the modified Pullicino formula in endovascular thrombectomy in acute anterior circulation large cerebral infarction-A two-center retrospective study[J]. J Stroke Cerebrovasc Dis, 2025, 34(1):108137. doi:10.1016/j.jstrokecerebrovasdis.2024.108137.
[3]	郭海霞. 银杏酮酯滴丸联合阿加曲班注射液治疗急性脑梗死的临床研究[J]. 中国基层医药, 2024, 31(1):14-18.
	GUO H X. Ginkgo ketone ester dropping pills combined with agatroban injection for the treatment of acute cerebral infarction[J]. Chin J Prim Med Pharm, 2024, 31(1):14-18. doi:10.3760/cma.j.cn341190-20230411-00278.
[4]	雷华斌, 马亚如, 王慧, 等. 通络化痰方治疗前循环脑梗死急性期(风痰阻络证)的疗效及对血流动力学的影响[J]. 中国中医急症, 2022, 31(8):1242-1245.
	LEI H B, MA Y R, WANG H, et al. Therapeutic efficacy and effect on haemodynamics of Tongluo Resolving Phlegm Formula in the treatment of acute stage of anterior circulation cerebral infarction (wind-phlegm obstruction syndrome)[J]. JETCM, 2022, 31(8):1242-1245. doi:10.3969/j.issn.1004-745X.2022.08.031.
[5]	中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9):666-682.
	Chinese Society of Neurology,Cerebrovascular Disease Group, Chinese Society of Neurology. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018[J]. Chinese Journal of Neurology, 2018, 51(9):666-682. doi:10.3760/cma.j.issn.1006-7876.2018.09.004.
[6]	中国中西医结合学会急救医学专业委员会. 中国急性缺血性脑卒中中西医急诊诊治专家共识[J]. 中华危重病急救医学, 2018, 30(3):193-197.
	Chinese Society for Integrated Chinese and Western Medicine First Aid Medicine Specialized Committee. Expert consensus of Chinese and Western medicine emergency treatment for acute ischemic stroke in China[J]. Chin Crit Care Med, 2018, 30(3):193-197. doi:10.3760/cma.j.issn.2095-4352.2018.03.001.
[7]	WINSTEIN C J, STEIN J, ARENA R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the american heart association/american stroke association[J]. Stroke, 2016, 47(6):98-169. doi:10.1161/STR.0000000000000098.
[8]	KWAH L K, DIONG J. National institutes of health stroke scale (NIHSS)[J]. J Physiother, 2014, 60(1):61. doi:10.1016/j.jphys.2013.12.012.
[9]	WADE D T, COLLIN C. The barthel adl index:a standard measure of physical disability?[J]. Int Disabil Stud, 1988, 10(2):64-67. doi:10.3109/09638288809164105.
[10]	郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社,2002:99-104.
	ZHENG X Y. Guiding principles for clinical research of New Chinese medicines (for trial implementation)[M]. Beijing: China Medical Science Press,2022:99-104.
[11]	WEI L, CAO Y, ZHANG K, et al. Prediction of progression to severe stroke in initially diagnosed anterior circulation ischemic cerebral infarction[J]. Front Neurol, 2021,12:652757. doi:10.3389/fneur.2021.652757.
[12]	YIN C, DING Y, SUN B, et al. Mechanical embolectomy for superior cerebellar artery embolism[J]. J Craniofac Surg, 2022, 33(3):846-849. doi:10.1097/SCS.0000000000008055.
[13]	李存明, 赵广峰, 张秀芳, 等. 桃红四物汤合涤痰汤对脑梗死急性期风痰瘀阻证脑血流动力学、血清脂蛋白A和同型半胱氨酸水平的影响[J]. 中华中医药学刊, 2020, 38(6):152-155.
	LI C M, ZHAO G F, ZHANG X F, et al. Effect of taohong siwu decoction and ditan decoction on cerebral hemodynamics and serum levels of lipoprotein a and homocysteine in acute cerebral infarction patients with syndrome of wind-phlegm-stasis[J]. Chinese Archives of Traditional Chinese Medicine, 2020, 38(6):152-155. doi:10.13193/j.issn.1673-7717.2020.06.036.
[14]	倪晨斐, 李成, 徐静艳. 醒脑开窍针刺法联合西医治疗急性前循环脑梗死的短期疗效观察[J]. 中国中医急症, 2022, 31(2):323-326.
	NI C F, LI C, XU J Y. Short-term efficacy observation on the treatment of acute anterior circulation cerebral infarction by waking up the brain and opening up the mind acupuncture method combined with western medicine[J]. JETCM, 2022, 31(2):323-326. doi:10.3969/j.issn.1004-745X.2022.02.037.
[15]	LIU F, LI H, HONG X, et al. Research progress of neuron-specific enolase in cognitive disorder: a mini review[J]. Front Hum Neurosci, 2024,18:1392519. doi:10.3389/fnhum.2024.1392519.
[16]	LANGEH U, SINGH S. Targeting s100b protein as a surrogate biomarker and its role in various neurological disorders[J]. Curr Neuropharmacol, 2021, 19(2):265-277. doi:10.2174/1570159X18666200729100427.
[17]	聂亚蒙, 张小强, 冯鹏展, 等. 依达拉奉右莰醇联合rt-PA静脉溶栓治疗超早期急性脑梗死的疗效及对预后的影响[J]. 天津医药, 2023, 51(7):766-771.
	NIE Y M, ZHANG X Q, FENG P Z, et al. Effects of edaravone dexborneol combined with rt-PA intravenous thrombolysis therapy on efficacy and prognosis of ultra-early acute cerebral infarction[J]. Tianjin Med J, 2023, 51(7):766-770. doi:10.11958/20221607.
[18]	HUWAIT E, AYOUB M, KARIM S. Investigation of the molecular mechanisms underlying the antiatherogenic actions of kaempferol in human thp-1 macrophages[J]. Int J Mol Sci, 2022, 23(13):7461. doi:10.3390/ijms23137461.
[19]	GARNIER O, VILGRAIN I. Dialogue between VE-cadherin and sphingosine 1 phosphate receptor1 (S1PR1) for protecting endothelial functions[J]. Int J Mol Sci, 2023, 24(4):4018. doi:10.3390/ijms24044018.
[20]	GAO H H, GAO L B, WEN J M. Correlations of MCP-1 -2518A>G polymorphism and serum levels with cerebral infarction risk:a meta-analysis[J]. DNA Cell Biol, 2014, 33(8):522-530. doi:10.1089/dna.2013.2263.
[21]	GERTZ K, KRONENBERG G, UHLEMANN R, et al. Partial loss of VE-cadherin improves long-term outcome and cerebral blood flow after transient brain ischemia in mice[J]. BMC Neurol, 2016, 16(1):144. doi:10.1186/s12883-016-0670-8.

组别	n	性别（男/女）	年龄/岁	ACCI发病时间/h
对照组	75	44/31	72.17±7.37	15.17±2.64
治疗组	75	41/34	72.49±7.39	15.33±2.11
t或χ²		0.244	0.266	0.409

组别	n	性别（男/女）	年龄/岁	ACCI发病时间/h
对照组	75	44/31	72.17±7.37	15.17±2.64
治疗组	75	41/34	72.49±7.39	15.33±2.11
t或χ²		0.244	0.266	0.409

组别	治愈	显效	进步	未愈	总有效/%
对照组	3	30	28	14	61（81.3）
治疗组	8	39	23	5	70（93.3）
χ²					4.881^＊

组别	治愈	显效	进步	未愈	总有效/%
对照组	3	30	28	14	61（81.3）
治疗组	8	39	23	5	70（93.3）
χ²					4.881^＊

组别	NIHSS
		治疗前		治疗1周		治疗2周	F
对照组		12.51±2.11		11.11±2.30^a		8.03±0.97^ab	123.684^＊＊
治疗组		12.43±2.08		10.05±2.20^a		6.69±0.90^ab	193.053^＊＊
t		0.234		2.867^＊＊		8.715^＊＊
组别	BI评分
组别	治疗前		治疗1周		治疗2周			F
对照组	52.08±6.73		58.41±7.33^a		68.29±8.14^ab			95.123^＊＊
治疗组	52.05±6.64		62.35±7.66^a		73.43±8.75^ab			146.198^＊＊
t	0.024		3.215^＊＊		3.720^＊＊